Article

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

2024-03-15

Abstract excerpt

<h4>ABSTRACT</h4> An economic evaluation was conducted to predict the economic and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 and Spring 2024 versus BNT162b2 variant-adapted vaccines in France. The number of symptomatic COVID-19 infections, hospitalizations, deaths, and long COVID cases, costs and quality-adjusted l...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d077e61a-663b-5245-b5cd-42cb78fa9411
DOI: 10.1101/2024.03.13.24304170

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceDOI 10.1101/2024.03.13.24304170Read

Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity Read

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United StatesSemantic proximity Read

Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in CanadaSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in CanadaSemantic proximity Read

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity Read

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesSemantic proximity Read

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United StatesSemantic proximity Read

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesSemantic proximity Read

Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity Read